Comparison of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) immunohistochemical expression and outcomes in canine nasal carcinomas treated with radiation therapy

J Vet Med Sci. 2022 Sep 5;84(9):1237-1243. doi: 10.1292/jvms.22-0106. Epub 2022 Jul 15.

Abstract

The expression of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) has been reported in human nasopharyngeal and canine nasal carcinomas. The present study measured EGFR and COX-2 expression and calculated correlations between these proteins and clinical variables and outcomes in dogs with nasal carcinoma treated with radiation therapy. Before treatment, the immunohistochemistry of EGFR and COX-2 was performed in 67 biopsied tissues from canine nasal carcinomas. The correlations between these protein levels, clinical variables, and outcomes were evaluated. EGFR and COX-2 were detected in 88.1% and 82.1% of our samples, respectively. Neither EGFR nor COX-2 was associated with T stage and cribriform plate destruction. Dogs with low EGFR levels had a significantly longer survival time than dogs with high EGFR expression (P=0.043). The COX-2 expression level was not significantly associated with survival times after radiation therapy (P=0.653). Overexpression of EGFR is negatively correlated with survival in dogs with nasal carcinoma. Future studies should identify tumor biomarkers to develop therapeutic targets for effective treatments for canine nasal carcinomas.

Keywords: cyclooxygenase-2; dog; epidermal growth factor receptor; nasal tumor; radiation therapy.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Carcinoma* / radiotherapy
  • Carcinoma* / veterinary
  • Cyclooxygenase 2 / metabolism
  • Dog Diseases* / pathology
  • Dogs
  • ErbB Receptors / metabolism
  • Humans
  • Immunohistochemistry
  • Nose Neoplasms* / radiotherapy
  • Nose Neoplasms* / veterinary

Substances

  • Cyclooxygenase 2
  • EGFR protein, human
  • ErbB Receptors